Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk's Victoza for the treatment of type 2 diabetes. The company expects to launch Victoza in Japan in the first half of 2010, upon completion of price negotiations.
Subscribe to our email newsletter
Victoza is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan.It is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes.
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: “The Japanese approval of Victoza represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk.
“We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza to provide superior glucose control with a low risk of hypoglycaemia.”